A Global, Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1117568 in Adults with Schizophrenia Who Warrant Inpatient Hospitalization

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521215-39-00

Acronym

NBI-1117568-SCZ3030

Enrollment

141

Registered

2025-11-07

Start date

2025-12-08

Completion date

Unknown

Last updated

2025-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Brief summary

Change from baseline in PANSS total score at Week 5

Detailed description

Change from baseline in CGI-S score at Week 5

Interventions

DRUGNBI-1117568

DRUGNBI-1117568 Placebo Capsule

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from baseline in PANSS total score at Week 5	—

Secondary

Measure	Time frame
Change from baseline in CGI-S score at Week 5	—

Countries

Bulgaria, Hungary, Romania

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026